TNGXTango Therapeutics, Inc.Signing up patients
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Non Small Cell Lung Cancer · Glioma Glioblastoma Multiforme · Glioma, Malignant · Solid Tumor · Non-Small Cell Adenocarcinoma · Lung Cancer · Brain Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 191 (planned)
- Started
- Mar 24, 2025
- Main results expected
- Mar 31, 2027
- Fully finished
- Sep 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1 Maximum Tolerated Dose
Measured over: 21 days
Phase 2 Anti-neoplastic Activity Single Agent
Measured over: 18 weeks
Phase 2 Anti-neoplastic Activity Combination Treatment
Measured over: 18 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06810544 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC